Importantly, STLNPs-Man@mRNA possessed the ability to downregulate cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) expression by blocking the CD206/CD45 axis, showing enhanced anti-tumor efficacy through combined immune checkpoint blockade therapy. Here, CTLA4 is linked to neoplasm.